Hemming Jocelyn D C, Hosford Mark, Shafer Martin M
Wisconsin State Laboratory of Hygiene , School of Medicine & Public Health , University of Wisconsin-Madison , 2601 Agricultural Drive , Madison , WI 53718 , USA . Email:
International Platinum Group Metals Association , Schiess-Staett-Strasse 30 , 80339 Munich , Germany.
Toxicol Res (Camb). 2019 Nov 20;8(6):802-814. doi: 10.1039/c9tx00242a. eCollection 2019 Nov 1.
The Direct Peptide Reactivity Assay (DPRA) was developed as a non-animal, relatively high throughput, screening tool for skin sensitization potential. Although the Adverse Outcome Pathway (AOP) for respiratory sensitization remains to be fully elucidated, it is recognized that the molecular initiation event for both skin and respiratory sensitization to low molecular weight chemicals involves haptenation with proteins. The DPRA examines the reactivity of a test compound to two model peptides (containing either cysteine or lysine) and consequently is able to screen for both skin and respiratory sensitization potential. The DPRA was primarily developed for and validated with organic compounds and assessment of the applicability of the assay to metal compounds has received only limited attention. This paper reports the successful application of the DPRA to a series of platinum compounds, including hexachloroplatinate and tetrachloroplatinate salts, which are some of the most potent chemical respiratory sensitizers known. Eleven platinum compounds were evaluated using the DPRA protocol as detailed by Lalko , with only minor modification. Two palladium compounds with structures similar to that of the platinum species studied and cobalt chloride were additionally tested for comparison. The hexachloroplatinate and tetrachloroplatinate salts showed exceptionally high reactivity with the cysteine peptide (EC values of 1.4 and 14 μM, respectively). However, for platinum compounds ( hydrogen hexahydroxyplatinate and tetraammineplatinum) where clinical and epidemiological evidence indicates limited sensitization potential, the cysteine DPRA showed only minor or no reactivity (EC values of 24 600 and >30 000 μM, respectively). The outcomes of the lysine peptide assays were less robust and where EC was measurable, values were substantially higher than the corresponding results from the cysteine assay. This work supports the value of peptide reactivity as a metric for assessment of platinum sensitization potential and therefore in screening of new platinum compounds for low or absent sensitization potential. Additional studies are required to determine whether the DPRA may be successfully applied to other metals. We provide details on method modifications and precautions important to the success of the DPRA in the assessment of metal reactivity.
直接肽反应性测定法(DPRA)是作为一种非动物、相对高通量的皮肤致敏潜力筛选工具而开发的。尽管呼吸道致敏的不良结局途径(AOP)仍有待充分阐明,但人们认识到,低分子量化学物质引起皮肤和呼吸道致敏的分子起始事件都涉及与蛋白质的半抗原化。DPRA检测受试化合物与两种模型肽(含半胱氨酸或赖氨酸)的反应性,因此能够筛选皮肤和呼吸道致敏潜力。DPRA最初是为有机化合物开发并经过验证的,而该测定法对金属化合物适用性的评估仅受到有限关注。本文报告了DPRA在一系列铂化合物中的成功应用,包括六氯铂酸盐和四氯铂酸盐,它们是已知的一些最有效的化学呼吸道致敏剂。按照Lalko详述的DPRA方案对11种铂化合物进行了评估,仅做了微小修改。另外还测试了两种结构与所研究的铂化合物类似的钯化合物以及氯化钴用于比较。六氯铂酸盐和四氯铂酸盐与半胱氨酸肽显示出极高的反应性(EC值分别为1.4和14 μM)。然而,对于临床和流行病学证据表明致敏潜力有限的铂化合物(六羟基铂酸氢盐和四氨合铂),半胱氨酸DPRA仅显示出轻微反应或无反应(EC值分别为24600和>30000 μM)。赖氨酸肽测定的结果不太稳定,在可测量EC的情况下,其值远高于半胱氨酸测定的相应结果。这项工作支持了肽反应性作为评估铂致敏潜力指标的价值,因此在筛选新的低致敏潜力或无致敏潜力的铂化合物方面具有价值。需要进一步研究以确定DPRA是否可以成功应用于其他金属。我们提供了方法修改和对DPRA评估金属反应性成功至关重要的注意事项的详细信息。